Scholarlink

<p>IDH-mutant gliomas show prognostic heterogeneity despite favorable overall outcomes, necessitating refined molecular classification. While the extracellular matrix (ECM) critically regulates tumor progression, immunity, and EMT, its prognostic significance in IDH-mutant gliomas remains largely unexplored. Here, we employed unsupervised clustering of ECM-related genes across multiple glioma cohorts, identifying two distinct molecular subtypes: ECM1 and ECM2. ECM1 correlated with worse prognosis, characterized by heightened immune infiltration, elevated EMT activity, aggressive radiological features (peritumoral edema/necrosis), and enhanced proliferation, angiogenesis, stemness, and matrix remodeling capacities. A four-gene signature (CLCF1, COL11A1, CSPG5, and SULF1) robustly stratified patient risk in validation cohorts. Subtype-specific analyses revealed divergent metabolic pathways and predicted differential drug sensitivities, highlighting therapeutic opportunities. Our findings establish ECM-driven heterogeneity as a key determinant of IDH-mutant glioma behavior, offering a novel molecular taxonomy to guide precision oncology through targeted ECM-related biomarkers and therapies.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

ECM-based molecular subtypes define prognostic, EMT status, and therapeutic diversity in IDH-mutant gliomas

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年8月27日

查看全文
  • Yanfei Wei,
  • Di Chen,
  • Qian Zhang,
  • Fenfen You,
  • YiLong Fu,
  • Lingjie Zheng,
  • Lingyang Zhang,
  • Nan Zhang,
  • Gaofeng Liang,
  • Jiaheng Yang,
  • Xiaojun Fu

摘要

IDH-mutant gliomas show prognostic heterogeneity despite favorable overall outcomes, necessitating refined molecular classification. While the extracellular matrix (ECM) critically regulates tumor progression, immunity, and EMT, its prognostic significance in IDH-mutant gliomas remains largely unexplored. Here, we employed unsupervised clustering of ECM-related genes across multiple glioma cohorts, identifying two distinct molecular subtypes: ECM1 and ECM2. ECM1 correlated with worse prognosis, characterized by heightened immune infiltration, elevated EMT activity, aggressive radiological features (peritumoral edema/necrosis), and enhanced proliferation, angiogenesis, stemness, and matrix remodeling capacities. A four-gene signature (CLCF1, COL11A1, CSPG5, and SULF1) robustly stratified patient risk in validation cohorts. Subtype-specific analyses revealed divergent metabolic pathways and predicted differential drug sensitivities, highlighting therapeutic opportunities. Our findings establish ECM-driven heterogeneity as a key determinant of IDH-mutant glioma behavior, offering a novel molecular taxonomy to guide precision oncology through targeted ECM-related biomarkers and therapies.